Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Entia Biosciences Inc. (OTC: ERGO).

Full DD Report for ERGO

You must become a subscriber to view this report.


Recent News from (OTC: ERGO)

Entia Biosciences, Inc. (OTCQB: ERGO) Enters into Exclusive Worldwide Licensing Agreement for its GROH Beauty Products Line
PORTLAND, Ore., Feb. 24, 2017 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCQB:ERGO) announced that it has licensed to GROH BEAUTY CORP of Deerfield Beach, Florida, the exclusive worldwide rights to manufacture and distribute its proprietary GROH ® beauty care product line.  Th...
Source: GlobeNewswire
Date: February, 24 2017 16:01
Entia Biosciences, Inc. (OTCQB: ERGO) Receives Notification of the Grant of European Patent it has Exclusively Licensed for Identifying the Ergothioneine Transporter and its Therapeutic Uses
PORTLAND, Ore., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCQB:ERGO) has been informed that the European Patent Office has granted European Patent Number 1 761 784 with the title “Identification of Ergothioneine Transporter and Therapeutic Uses Thereof” of th...
Source: GlobeNewswire
Date: November, 02 2016 15:20
Entia Biosciences, Inc. (OTCQB: ERGO) to Present Results of Chronic Kidney Disease Medical Food Clinical Study at American Society of Nephrology / Kidney Week 2016 Annual Meeting
PORTLAND, Ore., Oct. 06, 2016 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCQB:ERGO) was informed by the American Society of Nephrology (“ASN”) that its submission of “late breaking clinical trials” results has been accepted for presentation at the ASN Kidney...
Source: GlobeNewswire
Date: October, 06 2016 12:52
Preliminary clinical results for Entia Biosciences, Inc.'s new, proprietary ErgoD2® medical food show an average increase in kidney filtration rate of approximately 10% for over 75% of test subjects, after only three months
PORTLAND, Ore., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCQB:ERGO) Founder and Chief Science and Technology Officer, Dr. Marvin Hausman, has reported better-than-expected preliminary results in the Company’s chronic kidney disease study being conducted on the i...
Source: GlobeNewswire
Date: September, 26 2016 08:31
UPDATE -- Entia Biosciences, Inc. Begins Clinical Study of Proprietary ErgoD2® Medical Food Product to Demonstrate Improved Health for the More Than 25 Million Chronic Kidney Disease Sufferers in the U.S.
PORTLAND, Ore., Dec. 21, 2015 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCQB:ERGO) Founder and Chief Science and Technology Officer, Dr. Marvin Hausman, has reported greater-than-expected initial enrollment in Entia’s Chronic Kidney Disease study.  This milestone was achie...
Source: GlobeNewswire
Date: December, 21 2015 15:12
Entia Biosciences, Inc. Begins Clinical Study of Proprietary ErgoD2® Medical Food Product to Demonstrate Improved Health for the More Than 25 Million Chronic Kidney Disease Sufferers in the U.S.
PORTLAND, Ore., Dec. 21, 2015 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCQB:ERGO) Founder and Chief Science and Technology Officer, Dr. Marvin Hausman, has reported greater-than-expected initial enrollment in Entia’s Chronic Kidney Disease study.  This milestone was achie...
Source: GlobeNewswire
Date: December, 21 2015 08:50

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-16N/A0.015N/AN/A0
2018-08-15N/A0.015N/AN/A30
2018-08-14N/A0.015N/AN/A0
2018-08-13N/A0.015N/AN/A0
2018-08-10N/A0.015N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-0610,00030,00033.3333Cover
2018-08-034,0004,000100.0000Short
2018-07-209352,93531.8569Cover
2018-07-1922,800115,86519.6781Cover
2018-04-2310,00030,08033.2447Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ERGO.


About Entia Biosciences Inc. (OTC: ERGO)

Logo for Entia Biosciences Inc. (OTC: ERGO)

Entia develops patented, pharmaceutical grade organic compounds, including one known as ErgoD . Entia believes that ErgoD improves iron homeostasis and mitigates iron related disorders presenting in anemia, chronic kidney disease and select neurodegenerative diseases. Entia s goal is to clinically validate and commercialize ErgoD through the prescription Medical Food and OTC Supplement channels.

 

Contact Information

 

 

Current Management

  • Marvin S. Hausman, M.D. / Chief Scientific Officer
  • Carl J. Johnson / President, CEO
  • Timothy A. Timmins / EVP, COO, CFO
  • Marvin S. Hausman, M.D. / Chairman
  • Carl J. Johnson /
  • Elliot L. Shelton /

Current Share Structure

  • Market Cap: $572,235 - 03/09/2018
  • Authorized: 150,000,000 - 02/17/2017
  • Issue and Outstanding: 33,660,882 - 02/17/2017
  • Float: 11,519,390 - 02/17/2017

 


Recent Filings from (OTC: ERGO)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 20 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 04 2017
Filing Type: CT ORDERFiling Source: edgar
Filing Date: September, 05 2017
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: May, 19 2017
Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: May, 15 2017
Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: March, 31 2017
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 02 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 24 2017
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: February, 17 2017

 

 


Daily Technical Chart for (OTC: ERGO)

Daily Technical Chart for (OTC: ERGO)


Stay tuned for daily updates and more on (OTC: ERGO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ERGO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ERGO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ERGO and does not buy, sell, or trade any shares of ERGO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/